Biocon Limited Registered Office: 20th KM Hosur Road, Electronic City P.O., Bangalore - 560 100. www.biocon.com



UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30, 2013

(Rs. in Lakhs)

Year

31.03.2013

(Audited)

183 749

193.800

82.99

(1,790)

22 762

162,739

31 061

36,208

36.085

34,700

27,570

27 570 210,594

14.08

13.95 14.08

\sqcap	STATEMENT OF CONSO	LIDATED U	NAUDITED	RESULTS I	OR THE Q	UARTER A	ND	Г	_	STATEMENT OF STANDALON	IE UNAUE	OITED RESU	ths ended 2013 3.09.2012 after the project below) and project the control of the			
Par	CIV B		DED SEPTI		2013	(R	s. in Lakhs)	Pa	art I	CIV MONT				-		
SI. No.	Particulars	3 months ended 30.09.2013 (Unaudited)	Preceding 3 months ended 30.06.2013 (Unaudited)	Corresponding 3 months ended 30.09.2012 (Unaudited)	Year to date figures for current period ended 30.09.2013 (Unaudited)	Year to date figures for previous period ended 30,09,2012 (Unaudited)	Previous Year ended 31.03.2013 (Audited)	SI		Particulars	3 months ended 30.09.2013 (also refer note 5 below)	Preceding 3 months ended 30.06.2013 (also refer	3 months ended	figures for current period ended 30.09.2013	figures for previous period ended	r
	Income from operations	,		,	,	,	`	1				note 5 below)				-
\prod	a) Net Sales/ Income from Operations							\perp	4		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	1
Π	(Net of excise duty)	73,421	69,476	59,240	142,897	116,326	242,760	1		ncome from operations						
Π	b) Other Operating Income Total income from operations (net)	660	593 70,069	3,623 62,863	1,253 144,150	4,205 120,531	5,770 248,530	1		a) Net Sales/ Income from Operations (Net of excise duty)	53,417	52,289	46 140	105 706	80 300	, [
	Expenses	74,081	70,069	02,863	144,150	120,551	246,530	1		o) Other Operating Income	2,524	2,247				
	a) Cost of materials consumed	27,971	26,982	22,872	54,953	45,727	100,189	1		Total income from operations (net)	55,941	54,536	50,807	110,477	95,551	
Π	b) Purchases of stock in trade	3,618	2,327	1,014	5,945	3,173	6,931	2		Expenses a) Cost of materials consumed	22,990	22 757	10 288	45 747	30.010	
ш	c) Changes in inventories of finished							1		b) Purchases of stock in trade	3,400	2,068				
Π	goods, work-in-progress and	(2,092)	1,057	1,656	(1,035)	864	(2,652)	1		c) Changes in inventories of finished	(2,329)	1,122	1,819		1,130)
ш	stock in trade	44.240	44.530	0.457	22.040	40.504	20.044	1		goods, work-in-progress and stock in trade						
ш	d) Employee benefits expense e) Depreciation and amortisation expenses	11,310 5,009	11,530 4,825	9,457 4.461	22,840 9,834	18,584 8,730	38,944 17,930	1		d) Employee benefits expense	6,589	6,578	5.524	13.167	10.853	3
ш	f) Other expenses (net)	15,688	12,969	12,591	27,871	24,640	50,820	1		e) Depreciation and amortisation expenses	3,021	2,898	2,342	5,919	4,725	5
ш	Total Expenses	61,504	59,690	52,051	120,408	101,718	212,162	1	1	f) Other expenses Total Expenses	12,393 46,064	10,554 45,977	9,825 40,302	22,947 92,041	18,912 78,440	
3	Profit from operations before other		,		,] 3	. F	Profit from operations before other	40,004	45,977	40,302	92,041	/8,440	1
Π	income, finance costs and							`	i i	ncome,finance costs and exceptional items						
11 . 1	exceptional items (1-2)	12,577	10,379	10,812	23,742	18,813	36,368	Ι.		(1-2)	9,877	8,559	10,505	18,436		
4 5	Other Income Profit from ordinary activities before	1,173	2,248	1,331	2,635	2,923	5,266	1 4		Other Income Profit from ordinary activities before finance	2,030	2,686	968	4,716	2,560	1
	finance costs and exceptional items (3+4)	13,750	12,627	12,143	26,377	21,736	41.634	٦		costs and exceptional items (3+4)	11,907	11,245	11,473	23,152	19,671	.
6	Finance Costs	34	38	107	72	428	810	6		Finance Costs	24	22	17	46	73)
7	Profit from ordinary activities after							7		Profit from ordinary activities after finance costs before exceptional items (5-6)	11,883	11,223	11,456	23,106	19,598	
Π	finance costs before exceptional	42.746	42 500	42.026	26 205	24 200	40.024	8		Exceptional items (refer note 3 below)	- 11,005	11,225	11,430	25,100	15,550	-
8	items (5-6) Exceptional items (net) (refer note 2 and	13,716	12,589	12,036	26,305	21,308	40,824	9) 1	Profit from ordinary activities before tax						
°	3 below)	_	-	_	_	_	20,191	Ι,		(7+8) Tax Expense	11,883 2,895	11,223 2,450	11,456 2,620	23,106 5,345		
9	Profit from ordinary activities						·	I 1	11 I	Net profit for the period / year (9-10)	8,988	8,773	8,836	17,761		
ш	before tax (7+8)	13,716	12,589	12,036	26,305	21,308	61,015	1	2 Ir	mpact of scheme of merger for earlier period						
10	Tax Expense	3,189	2,971	3,042	6,160	4,415	9,750	Ι.		refer note 5 below)	554	-	-	554	-	1
11	Net profit for the period/year (9-10)	10,527	9,618	8,994	20,145	16,893	51,265	'		Profit for the period after giving impact of scheme of merger for earlier year (11+12)	9,542	8,773	8,836	18,315	15,720	,
12	Minority interest Net profit after tax and minority	(312)	(268)	(29)	(580)	(48)	(383)	1	4 P	Paid-up equity share capital (Face Value of Rs.5	10,000	10,000	10,000	10,000		
	interest (11+12)	10,215	9,350	8,965	19,565	16,845	50,882	Ι.		each)						
14	Paid-up equity share capital (Face value						·	Ι'	3 F	Reserve excluding revaluation reserves as per palance sheet of previous accounting year						
ш	of Rs. 5 each)	10,000	10,000	10,000	10,000	10,000	10,000	1	16 E	Earnings per share (of Rs 5 each) (not						
15	Reserve excluding revaluation reserves as per balance sheet						259,373	1		annualised)						
$ \cdot $	of previous accounting year						233,373			(a)Basic (after giving impact of scheme of merger for earlier year)	4.87	4.48	4.51	9.34	8.03	3
16	Earnings per share (of Rs 5 each)							1	(1	(b)Diluted (after giving impact of scheme of						
$ \cdot $	(not annualised)									merger for earlier year)	4.83	4.44	4.49	9.27	7.97	
$ \cdot $	(a)Basic	5.21	4.77	4.59	9.98	8.61	25.99			c)Basic (before giving impact of scheme of merger for earlier year)	4.58	4,48	4.51	9.06	8.03	3
$ \cdot $	(b)Diluted See accompanying note to the	5.17	4.73	4.56	9.90	8.54	25.75		(0	d)Diluted (before giving impact of scheme of						
$ \cdot $	See accompanying note to the financial results						 			merger for earlier year)	4.55	4.44	4.49	8.99	7.97	
╵┷								1	1 s	See accompanying note to the financial results		1				

Part I	

l		Select information for the period						
	A 1	PARTICULARS OF SHAREHOLDING Public Shareholding - Number of Shares - Percentage of shareholding	78,051,554 39.03%	78,075,854 39,04%	78,075,854 39,04%	78,051,554 39,03%	78,075,854 39,04%	78,075,854 39.04%
	2	Promoters and Promoter Group Shareholding a) Pledged/encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of the promoter and	40,000	-	-	40,000	-	-
l		promoter group) - Percentage of shares (as a % of the total	0.03%	-	-	0.03%	-	-
l		sharecapital of the company) b) Non-encumbered	0.02%	-	-	0.02%	-	-
l		Number of Shares Percentage of shares (as a % of the total shareholding of the promoter and	121,908,446	121,924,146	121,924,146	121,908,446	121,924,146	121,924,146
l		promoter group) - Percentage of shares (as a % of the total	99.97%	100%	100%	99.97%	100%	100%
l		share capital of the company)	60.95%	60.96%	60.96%	60.95%	60.96%	60.96%

- 1. The unaudited financial results of the Company and the unaudited consolidated financial results for the quarter and six months ended September 30, 2013 have been subjected to limited review by the statutory auditors. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 24, 2013.
- 2. During the year ended March 31, 2012, based on an evaluation of the prevalent regulatory framework, industry practices and ethics/governance requirements relating to clinical trials and the regulatory submissions already initiated / filed, Biocon SA, a wholly owned subsidiary of the Company (together referred to as "Biocon"), had determined that it had continuing obligations to complete clinical development and regulatory activities relating to Biocon's Biosimilar Insulin portfolio comprising of Biosimilar Insulin analogs. Accordingly, pursuant to the termination of the customer contract in March 2012, Biocon deferred the remainder of the upfront amounts received from the customer, to be recognized in the consolidated statement of profit and loss in subsequent periods in line with costs incurred towards such clinical trials and development activities, in February 2013, Biocoon SA entered into an agreement with another customer for the global development and commercialization of Biosimilar insulin Analogs (the Agreement), granting the customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain the customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain customer exclusive rights to commercialize Biosimilar Biosim development and regulatory activities in respect of such Biosimilar Insulin Analogs is now being carried out in accordance with the Agreement. As such, Biocon has therefore determined that it does not have continuing obligations for clinical trials and development Agreement. As such, blocon has therefore determined that it does not have commonly proportion of estimated future development spends on these programs, Rs 21,501 lakhs of deferred revenues allocated to Biosimilar Insulin Analogs. Accordingly, based on an allocation in proportion of estimated future development spends on these programs, Rs 21,501 lakhs of deferred revenues allocated to Biosimilar Insulin Analogs (net of amounts already 9. Prior period / year figures have been reclassified wherever required to conform to the classification of the current period.

recognized in the consolidated statement of profit and loss) was recognized as an exceptional income in the consolidated statement of profit and loss for the year ended March 31, 2013 and is disclosed under exceptional items. Considering that Biocon has continuing obligations respect of Biosmillar Insulin, the remainder of deferred amounts as at March 31, 2013, of Rs 28,001 lakhs, continues to be recognized in the consolidated statement of profit and loss in line with costs to be incurred towards clinical trials and development activities of Biosimila Insulin. For the guarter ended June 30, 2013 and September 30, 2013, of the deferred amounts, Rs 338 lakhs and Rs 614 lakhs, respectively have been netted off against expenses incurred towards such clinical trial and development activities. The statutory auditors of the Compan have drawn an Emphasis of Matter in this regard, in their Limited Review report on the consolidated unaudited financial results.

- 3. Pursuant to certain developments, on a prudent basis, the Company created a provision of Rs 1,385 lakhs and Rs 1,310 Lakhs for diminution in the value of investments in latrica Inc in the standalone and consolidated financial statements, respectively for the year ended March 31
- 4. Total income from operations for quarter and six month period ended September 30, 2012, and for the year ended March 31, 2013 (standalone and consolidated) include Rs 3,064 Lakhs, towards one time income / compensation from few parties.
- 5. On July 25, 2012, the Board of Directors of the Company approved a scheme of amalgamation ("the Scheme") of Biocon Biopharmaceuticals Limited ("BBL"), a wholly owned subsidiary, with the Company under sections 391 and 394 of the Companies Act, 1956. During the quarter ended September 30, 2013, the Honorable High Court of Karnataka ("the Court") approved the aforesaid Scheme with Appointed Date as April 1, 2012. Accordingly, the assets and liabilities, and deficit in the Statement of Profit and Loss of BBL of Rs 1,028 lakhs as at Appointed. Date have been recorded at their carrying values under the Pooling of Interest method as prescribed by Accounting Standard 14 - Accounting for Amalgamation ('AS 14'), and difference between value of investments and the amount of share capital of BBL amounting to Rs 357 lakh: has been debited to the Reserves and Surplus of the Company. Post receipt of the requisite approvals, the Company has considered th operations of BBL from April 1, 2012 as its own operations. Accordingly, profit after tax amounting to Rs 554 lakhs (net of tax of Rs 579 lakhs) relating to operations of BBL from April 1, 2012 to March 31, 2013, have been accounted for in the standalone results for quarter and six months ended September 30, 2013. Further, the earlier published standalone results for the preceding quarter ended June 30, 2013 have been restated to incorporate the operations of BBL to give effect of the amalgamation.
- 6. During the quarter ended September 30, 2013, the Company paid dividend of Rs 7.50 per share amounting to Rs 15,000 Lakhs for the year 2012-13 representing 150% dividend.
- 7. Segment Reporting: a. Standalone financial results: The Company operates in a single business segment of biopharmaceuticals. b. Consolidated financial results: The primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of products, risks and returns, organizational structure and internal financial reporting systems.
- 8. Information on investor complaints

	3 months ended 30.09.2013
Pending at the beginning of the quarter	-
Received during the quarter	16
Disposed of during the quarter	16
Remaining unresolved at the end of the quarter	=

SEGMENT DETAILS OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH PERIOD ENDED SEPTEMBER 30, 2013 (Rs. in Lakhs)

Particulars	3 months ended 30,09,2013	Preceding 3 months ended 30.06.2013	Corresponding 3 months ended 30,09,2012	Year to date figures for current period ended 30.09.2013	Year to date figures for previous period ended 30.09.2012	Previous Year ended 31,03,2013
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment revenue						
a. Pharma	54,991	54,341	49,688	109,332	94,861	191,831
b. Contract Research &	19,567	16,034	13,711	35,601	26,836	58,829
Manufacturing Services						
Total	74,558	70,375	63,399	144,933	121,697	250,660
Less: Inter-segment revenue	477	306	536	783	1,166	2,130
Net sales / Income from						
continuing operations	74,081	70,069	62,863	144,150	120,531	248,530
Segment results						
Profit before interest, depreciation						
and tax from each segment						
a. Pharma	22,915	21,813	20,482	44,728	37,491	75,444
b. Contract Research &						
Manufacturing Services	7,532	5,394	5,268	12,926	10,014	21,081
Total	30,447	27,207	25,750	57,654	47,505	96,525
Less: Interest	34	38	107	72	428	810
Depreciation and amortisation	5,009	4,825	4,461	9,834	8,730	17,930
Unallocated corporate expenses	12,861	12,003	10,477	24,078	19,962	42,227
Unallocated corporate income	(1,173)	(2,248)	(1,331)	(2,635)	(2,923)	(5,266)
Profit before tax and						
before exceptional items	13,716	12,589	12,036	26,305	21,308	40,824
Capital employed						
a. Pharma	136,455	133,267	123,920	136,455	123,920	128,336
b. Contract Research &						
Manufacturing Services	59,119	54,113	34,473	59,119	34,473	55,045
c. Unallocable	104,481	100,773	86,770	104,481	86,770	92,612
d. Minority interest	(7,110)	(6,796)	(428)	(7,110)	(428)	(6,530)
Total capital employed	292,945	281,357	244,735	292,945	244,735	269,463

Tc	otal capital employed	292,94	45 2
9	Standalone Statement of Ass	ets and Lia	bilities
	Particulars	As at September 30, 2013 (Unaudited)	As at March 31, 2013 (Audited)
Α	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share capital	10,000	10,000
	(b) Reserves and surplus	228,443	210,684
	Sub total-Shareholders' funds	238,443	220,684
2	Non-current liabilities		
	(a) Long-term borrowings	3,238	3,996
	(b) Deferred tax liabilities (net)	3,054	3,020
	(c) Other long-term liabilities	13,343	10,830
	Sub total-Non-current liabilities	19,635	17,846
3	Current liabilities		
	(a) Short-term borrowings	6,283	7,727
	(b) Trade payables	31,007	26,504
	(c) Other current liabilities (d) Short-term provisions	7,612 7,326	6,794 21,768
	Sub total-Current liabilities	52,228	62,793
	TOTAL - EQUITY AND LIABILITIES	310,306	301,323
_	•	310,300	301,323
_	ASSETS		
1	Non-current assets		
	(a) Fixed Assets	103,278	90,260
	(b) Non-current investments (c) Long -term loans and advances	14,486 43,042	16,599 47,128
	(d) Other non-current assets	340	47,120
	Sub total-Non-current assets	161,146	153,987
,	Current assets	101,140	133,307
-	(a) Current investments	42,813	45,298
	(b) Inventories	40,636	35,887
	(c) Trade receivables	46,352	42,698
	(d) Cash and cash equivalents	10,766	17,925
	(e) Short -term loans and advances	7,853	5,104
	(f) Other current assets	740	424
	Sub total-Current assets	149,160	147,336
	TOTAL - ASSETS	310,306	301,323

Place: Bangalore

Date: October 24, 2013

57	244,735	292,945	244,735	269,4
C	onsolidated :	Statement of A	Assets and L	iabilitie (Rs. in Lai
	Partio	culars	As at September 30, 2013 (Unaudited)	As at March 31, 201 (Audited
Α	EQUITY AND LIA	ABILITIES		
1	Shareholders' (a) Share capital (b) Reserves and s	surplus	10,000 282,945	10,00 259,46 269,4 6
2	Minority inter		292,945 7.110	6.53
3	Non-current lia		7,110	0,33
	(a) Long-term bor (b) Deferred tax li	rowings	33,538 3,605	16,39 4,12
	(c) Other long-ter (d) Long-term pro Sub total-Non-c	m liabilities wisions	48,796 634 86,573	42,37 39 63,28
4	Current liabilit		86,573	03,20
	(a) Short-term bo (b) Trade payable: (c) Other current (d) Short-term pro	s liabilities ovisions	6,909 39,297 33,785 10,433	8,48 34,54 34,65 24,65
	Sub total - Curre	ent liabilities AND LIABILITIES	90,424 477,052	102,33 441,61
В	ASSETS	AND LIABILITIES	4/7,032	441,61
1	Non-current ass	ets		
	(a) Fixed assets (b) Goodwill on c (c) Non-current in (d) Long- term loa (e) Other non-cur	onsolidation vestments ans and advances	204,667 1,216 6,457 30,327 5,241	181,06 1,21 6,44 24,83 4,05
	Sub total-Non-c	urrent assets	247,908	217,61
2	Current assets			
	(a) Current invest (b) Inventories (c) Trade receivab (d) Cash and cash (e) Short term loa (f) Other current a	les equivalents ns and advances	47,563 42,286 58,352 65,848 6,229 8,866	52,20 39,84 50,96 67,28 8,14 5,55
	Sub total-Currer	nt assets	229,144	224,00
ı	TOTAL - ASSETS		477,052	441,61

Sd/-

Kiran Mazumdar Shaw Chairman & Managing Director